Exhibit 99.1
Teleflex ® | NEWS | |
155 South Limerick Road, Limerick, PA 19468 USA — Phone: 610-948-5100 — Fax: 610-948-5101 |
Contact: | Jake Elguicze Senior Director, Investor Relations 610-948-2836 |
FOR IMMEDIATE RELEASE | April 28, 2009 |
TELEFLEX REPORTS FIRST QUARTER 2009 RESULTS
Reaffirms Full Year EPS and Cash Flow Guidance
First Quarter Diluted EPS from Continuing Operations Excluding Special Items — $0.76
per share, up 17%
First Quarter GAAP Diluted EPS from Continuing Operations of $0.66 per share, up 74%
Limerick, PA —Teleflex Incorporated (NYSE: TFX) today announced financial results for the first quarter ended March 29, 2009. Revenues from continuing operations were $469.7 million compared to $542.1 million in the first quarter of 2008, down 13% driven by a decline in core revenue of 8% and an unfavorable currency impact of 5%. Core revenue decline by segment was Medical 4%, Aerospace 27%, and Commercial 13%.
Income from continuing operations excluding special charges increased 17% to $30.2 million or $0.76 per diluted share compared to $25.7 million or $0.65 per diluted share in the prior year quarter. Income from continuing operations attributable to common shareholders including special charges increased to $26.4 million or $0.66 per diluted share compared to $15.0 million or $0.38 per diluted share in the prior year. Results for the period included the charges listed in the reconciliation table below.
Income from discontinued operations attributable to common shareholders was $189.1 million or $4.74 per diluted share compared to $7.9 million or $0.20 per diluted share in the prior year quarter. 2009 results from discontinued operations include a gain net of tax, of $178.6 million, or $4.48 per diluted share from the sale of the 51% ownership in Airfoil Technologies International — Singapore Pte. Ltd. (“ATI”).
Net income attributable to common shareholders in the first quarter of 2009 was $215.5 million and diluted earnings per share available to common shareholders were $5.40 compared to $22.9 million and $0.58 per diluted share in the prior year quarter.
Cash flow from continuing operations for the quarter used net cash of $4.5 million. Excluding a tax payment of $47.4 million related to the divestiture of the automotive and industrial businesses, cash flow from continuing operations for the first quarter of 2008 was $27.2 million.
“Teleflex was able to generate 17% adjusted earnings growth despite operating in what are unprecedented economic times,” said Jeffrey P. Black, chairman and chief executive officer. “In addition, as a result of the divestiture of ATI during the quarter, we were able to further reduce our debt by approximately $240 million, improving our balance sheet to provide additional flexibility to support future growth and eliminating the requirement of further debt payments until September 2010.”
1
Black stated, “We continue to expect to deliver low to mid-single digit core revenue growth within our Medical business for the full year notwithstanding the challenges experienced in certain product categories during the first quarter which negatively impacted growth. Due to the increasing uncertainty in the end markets served by our Aerospace and Commercial Segments, we expect continued revenue challenges and will remain vigilant with our cost containment initiatives in these businesses.”
Added Black, “Despite the softness in revenue during the quarter and considering the action plans initiated to improve working capital, we are reaffirming our 2009 annual guidance for earnings per share of $3.25 to $3.55 per diluted share excluding special charges and cash flow from continuing operations of $210 to $220 million.”
Business Segment Commentary
Medical Segment
Medical Segment revenues of $340.5 million for the first quarter represented a decrease of 9% versus the previous year with a core decline of 4% and negative impact from currency of 5%. The decrease in core revenue was primarily due to reduced sales of respiratory products in North America as a result of a less severe flu season, distributor inventory reductions, lower sales of cardiac care products driven by a product recall, and a decline in orthopedic devices sold to medical OEM’s. These declines were partially offset by higher sales of urology and surgical products.
Medical Segment sales by product group were comprised of the following:
Three Months | Three Months | QTD Change | QTD Change | |||||||||||||||||||||||
Ended | Ended | Including F/X | Excluding F/X | |||||||||||||||||||||||
March 29, 2009 | March 30, 2008* | |||||||||||||||||||||||||
Critical Care | $ | 218.1 | $ | 243.7 | (11 | ) | % | (5 | ) | % | ||||||||||||||||
Surgical | 69.0 | 72.9 | (5 | ) | % | 1 | % | |||||||||||||||||||
Cardiac Care | 15.4 | 18.2 | (15 | ) | % | (10 | ) | % | ||||||||||||||||||
OEM | 34.2 | 36.3 | (6 | ) | % | (4 | ) | % | ||||||||||||||||||
Other | 3.8 | 3.0 | 27 | % | 46 | % | ||||||||||||||||||||
Total Sales | $ | 340.5 | $ | 374.1 | (9 | ) | % | (4 | ) | % | ||||||||||||||||
Adjusted segment operating profit declined to $70.8 million from $78.1 million in the prior year. The decline resulted from lower revenues and the stronger U.S. dollar which was partially offset by lower selling, general, administrative and manufacturing costs attributable primarily to synergies from the Arrow integration activities. Adjusted segment operating margins in the quarter were 20.8% versus 20.9% in the prior year quarter. A reconciliation of adjusted segment operating profit and margins are noted in the table below.
Aerospace Segment
Aerospace Segment revenues declined 34% to $43.7 million from $66.3 million in the same period last year primarily driven by a decrease in sales of cargo loading systems and cargo containers. An unfavorable currency impact of 7% also contributed to the decline.
Segment operating profit decreased to $3.0 million from $4.9 million principally due to the decline in revenues. Segment operating margin for the quarter was 6.9% versus 7.4% in the prior year first quarter.
Commercial Segment
Commercial Segment revenues declined 16% to $85.4 million from $101.8 million in the same period last year. Core growth in sales of power systems and rigging services products of 35% and 1%, respectively, was more than offset by a 34% decline in sales of marine products. Unfavorable currency translation contributed 3% to the decline.
During the first quarter of 2009, operating profit in the Commercial Segment increased to $4.7 million from $2.8 million, principally due to increases in the power systems business more than offsetting further declines in marine. Segment operating margin rose to 5.5% from 2.8% in the prior year quarter.
Business Outlook for 2009
The company reaffirms its full year 2009 guidance for earnings per share from continuing operations of $3.25 to $3.55 per diluted share, excluding special charges. Special charges for 2009 are expected to be in the range of $0.30 to $0.40 per diluted share. Earnings per share attributable to common shareholders including special charges, are expected to be in the range of $2.85 to $3.25 per diluted share.
In addition, the company also reaffirms full year 2009 guidance of cash flow from continuing operations of $210 million to $220 million.
First Quarter Conference Call Webcast and Additional Information
As previously announced, Teleflex will comment on its first quarter results on a conference call to be held Tuesday, April 28, 2009, at 9:00 a.m. (ET). The call will be available live and archived on the company’s website atwww.teleflex.com and accompanying presentations will be posted prior to the call. An audio replay will be available until May 3, 2009 by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 98105977.
Additional Notes
Core growth includes activity of a purchased company beyond the initial twelve months after the date of acquisition. Core growth excludes the impact of translating the results of international subsidiaries at different currency exchange rates from year to year, and the activity of companies that have been divested within the most recent twelve month period.
Certain financial information is presented on a rounded basis, which may cause minor differences.
Segment operating profit includes a segment’s net revenues reduced by its materials, labor and other product costs along with the segment’s selling, engineering and administrative expenses and noncontrolling interest. Unallocated corporate expenses, gains or losses on sales of assets, restructuring and impairment charges, interest income and expense and taxes on income are excluded from the measure.
Segment commentary excludes the impact of discontinued operations, items included in restructuring and impairment charges, losses and other charges, and fair market value adjustments for inventory as disclosed in the condensed consolidated statements of income.
• Certain reclassifications within product categories have been made to 2008 results to conform with current year presentation.
Notes on Non-GAAP Financial Measures
This press release addresses certain non-GAAP measures. We use these financial measures for internal managerial purposes, when publicly providing guidance on possible future results, and as a means to evaluate period-to-period comparisons. These financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures.
This press release includes financial measures which exclude the effect of charges associated with our restructuring programs, charges related to the Arrow acquisition, and (gain)/loss on sale of assets and other charges. Management believes these measures are useful to investors because they eliminate items that do not reflect Teleflex’s day-to-day operations. Tables reconciling these non-GAAP measures to the most directly comparable GAAP measures are set forth below.
Three Months Ended | Three Months Ended | |||||||||||||||||||||||||||||||
March 29, 2009 | March 30, 2008 | |||||||||||||||||||||||||||||||
Continuing Operations | Continuing Operations | |||||||||||||||||||||||||||||||
(dollars in thousands, except per share) | ||||||||||||||||||||||||||||||||
Income and diluted earnings per share attributable to common | ||||||||||||||||||||||||||||||||
shareholders | $ | 26,414 | $ | 0.66 | $ | 15,021 | $ | 0.38 | ||||||||||||||||||||||||
Restructuring and impairment charges | 2,463 | 8,856 | ||||||||||||||||||||||||||||||
Tax benefit | (716 | ) | (2,822 | ) | ||||||||||||||||||||||||||||
Restructuring and impairment charges, net of tax | 1,747 | 0.04 | 6,034 | 0.15 | ||||||||||||||||||||||||||||
Losses and other charges (A) | 3,226 | 294 | ||||||||||||||||||||||||||||||
Tax benefit | (1,211 | ) | (75 | ) | ||||||||||||||||||||||||||||
Losses and other charges, net of tax | 2,015 | 0.05 | 219 | 0.01 | ||||||||||||||||||||||||||||
Fair market value inventory adjustment (B) | — | 6,936 | ||||||||||||||||||||||||||||||
Tax benefit | — | (2,487 | ) | |||||||||||||||||||||||||||||
Fair market value inventory adjustment, net of tax | — | — | 4,449 | 0.11 | ||||||||||||||||||||||||||||
Income and diluted earnings per share, excluding restructuring and impairment charges, losses and other charges, and fair market value inventory adjustment | $ | 30,176 | $ | 0.76 | $ | 25,723 | $ | 0.65 | ||||||||||||||||||||||||
(A) In 2009, losses and other charges principally relate to loss on sale of assets and restructuring related costs associated with the Arrow acquisition. In 2008, losses and other charges relate to restructuring related costs associated with the Arrow acquisition.
(B) The fair market value inventory adjustment reflects the absorption of the residual Arrow inventory purchase price adjustment from acquisition date.
Adjusted Medical Segment Operating Profit and Margins
Three Months | ||||||||||||
Three Months Ended | Ended | |||||||||||
March 29, 2009 | March 30, 2008 | |||||||||||
(dollars in thousands) | ||||||||||||
Medical Segment operating profit as reported | $ | 70,193 | $ | 70,912 | ||||||||
Medical Segment operating margin as reported | 20.6 | % | 19.0 | % | ||||||||
Add: Fair market value inventory adjustment | — | 6,936 | ||||||||||
Add: Integration costs not qualified for restructuring | 629 | 276 | ||||||||||
Adjusted Medical Segment operating profit | $ | 70,822 | $ | 78,124 | ||||||||
Adjusted Medical Segment operating margin | 20.8 | % | 20.9 | % |
YTD Reconciliation of Teleflex Cash Flow from Continuing Operations
Three Months Ended | Three Months Ended | |||||||||||||||||||||||
March 29, 2009 | March 30, 2008 | |||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
Cash flow from continuing operations as reported | $ | (4,454 | ) | $ | (20,250 | ) | ||||||||||||||||||
Add: Tax payment on gain on sale of automotive and industrial businesses | — | 47,402 | ||||||||||||||||||||||
Adjusted cash flow from continuing operations | $ | (4,454 | ) | $ | 27,152 | |||||||||||||||||||
About Teleflex Incorporated
Teleflex is a diversified company that designs, manufactures and distributes quality engineered products and services for the medical, aerospace and commercial markets worldwide. Teleflex employs approximately 13,000 people worldwide who focus on providing innovative solutions for customers. Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com.
Caution Concerning Forward-looking Information
This press release contains forward-looking statements, including, but not limited to, statements relating to expected core revenue growth within our Medical business; expected revenue challenges with respect to our Aerospace and Commercial segments; our forecast of diluted earnings per share from continuing operations excluding special charges for 2009; expected range of special charges for 2009; our forecast of diluted earnings per share from continuing operations attributable to common shareholders including special charges for 2009; and expected cash flow from continuing operations for 2009. Actual results could differ materially from those in these forward-looking statements due to, among other things, conditions in the end markets we serve, customer reaction to new products and programs, our ability to achieve sales growth, price increases or cost reductions; our ability to realize efficiencies; changes in material costs and surcharges; unanticipated difficulties in connection with consolidation of manufacturing and administrative functions; unanticipated difficulties, expenditures and delays in connection with the integration of Arrow International, including delays in the implementation of integration programs and adverse customer and shareholder reaction; unanticipated difficulties, expenditures and delays in complying with government regulations applicable to our businesses, including unanticipated costs and difficulties in connection with the resolution of issues related to the FDA corporate warning letter issued to Arrow; our ability to meet our debt obligations; changes in general and international economic conditions; and other factors described in Teleflex’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10K.
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three Months Ended | ||||||||||||||||||||
March 29, | March 30, | |||||||||||||||||||
2009 | 2008 | |||||||||||||||||||
(Dollars and shares in thousands, | ||||||||||||||||||||
except per share) | ||||||||||||||||||||
Net revenues......................................................................................... | $ | 469,675 | $ | 542,110 | ||||||||||||||||
Materials, labor and other product costs......................................................... | 273,551 | 328,671 | ||||||||||||||||||
Gross profit.......................................................................................... | 196,124 | 213,439 | ||||||||||||||||||
Selling, engineering and administrative expenses.............................................. | 128,764 | 147,573 | ||||||||||||||||||
Net loss on sales of businesses and assets........................................................ | 2,597 | 18 | ||||||||||||||||||
Restructuring and other impairment charges.................................................... | 2,463 | 8,856 | ||||||||||||||||||
Income from continuing operations before interest and taxes................................ | 62,300 | 56,992 | ||||||||||||||||||
Interest expense.................................................................................... | 25,402 | 31,083 | ||||||||||||||||||
Interest income.................................................................................... | (214 | ) | (961 | ) | ||||||||||||||||
Income from continuing operations before taxes............................................. | 37,112 | 26,870 | ||||||||||||||||||
Taxes on income from continuing operations................................................... | 10,462 | 11,662 | ||||||||||||||||||
Income from continuing operations.............................................................. | 26,650 | 15,208 | ||||||||||||||||||
Operating income from discontinued operations (including gain on disposal of $275,787 and $0, respectively).................. .............................................. | 297,975 | 15,195 | ||||||||||||||||||
Taxes on income from discontinued operations.................................................. | 99,018 | 406 | ||||||||||||||||||
Income from discontinued operations........................................................... | 198,957 | 14,789 | ||||||||||||||||||
Net income............................................................. .............................. | 225,607 | 29,997 | ||||||||||||||||||
Less: Net income attributable to noncontrolling interest...................................... | 236 | 187 | ||||||||||||||||||
Income from discontinued operations attributable to noncontrolling interest...... | 9,860 | 6,867 | ||||||||||||||||||
Net income attributable to common shareholders............................................. | $ | 215,511 | $ | 22,943 | ||||||||||||||||
Earnings per share available to common shareholders: | ||||||||||||||||||||
Basic: | ||||||||||||||||||||
Income from continuing operations ........................................................ | $ | 0.67 | $ | 0.38 | ||||||||||||||||
Income from discontinued operations .................................................... | $ | 4.76 | $ | 0.20 | ||||||||||||||||
Net income .................................................................................... | $ | 5.43 | $ | 0.58 | ||||||||||||||||
Diluted: | ||||||||||||||||||||
Income from continuing operations ........................................................ | $ | 0.66 | $ | 0.38 | ||||||||||||||||
Income from discontinued operations .................................................... | $ | 4.74 | $ | 0.20 | ||||||||||||||||
Net income .................................................................................... | $ | 5.40 | $ | 0.58 | ||||||||||||||||
Dividends per share................................................................................ | $ | 0.340 | $ | 0.320 | ||||||||||||||||
Weighted average common shares outstanding: | ||||||||||||||||||||
Basic.............................................................................................. | 39,692 | 39,454 | ||||||||||||||||||
Diluted........................................................................................... | 39,876 | 39,709 | ||||||||||||||||||
Amounts attributable to common shareholders: | ||||||||||||||||||||
Income from continuing operations, net of tax | $ | 26,414 | $ | 15,021 | ||||||||||||||||
Discontinued operations, net of tax | 189,097 | 7,922 | ||||||||||||||||||
Net income | $ | 215,511 | $ | 22,943 | ||||||||||||||||
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
March 29, | December 31, | |||||||||||||||||||||||
2009 | 2008 | |||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||
ASSETS | ||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||
Cash and cash equivalents......................................................................... | $ | 143,051 | $ | 107,275 | ||||||||||||||||||||
Accounts receivable, net.......................................................................... | 288,971 | 311,908 | ||||||||||||||||||||||
Inventories, net..................................................................................... | 406,829 | 424,653 | ||||||||||||||||||||||
Prepaid expenses and other current assets.................................................... | 19,658 | 21,373 | ||||||||||||||||||||||
Income taxes receivable............................................................................ | 11,004 | 17,958 | ||||||||||||||||||||||
Deferred tax assets................................................................................ | 64,407 | 66,009 | ||||||||||||||||||||||
Assets held for sale.................................................................................. | 7,773 | 8,210 | ||||||||||||||||||||||
Total current assets........................................................................... | 941,693 | 957,386 | ||||||||||||||||||||||
Property, plant and equipment, net................................................................... | 332,407 | 374,292 | ||||||||||||||||||||||
Goodwill................................................................................................. | 1,447,005 | 1,474,123 | ||||||||||||||||||||||
Intangibles and other assets........................................................................... | 1,062,419 | 1,090,852 | ||||||||||||||||||||||
Investments in affiliates............................................................................... | 15,886 | 28,105 | ||||||||||||||||||||||
Deferred tax assets................................................................................... | 6,864 | 1,986 | ||||||||||||||||||||||
Total assets..................................................................................... | $ | 3,806,274 | $ | 3,926,744 | ||||||||||||||||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||
Current borrowings................................................................................. | $ | 5,973 | $ | 108,853 | ||||||||||||||||||||
Accounts payable................................................................................. | 109,710 | 139,677 | ||||||||||||||||||||||
Accrued expenses................................................................................. | 111,724 | 125,183 | ||||||||||||||||||||||
Payroll and benefit-related liabilities............................................................ | 65,039 | 83,129 | ||||||||||||||||||||||
Derivative liabilities.............................................................................. | 22,972 | 27,370 | ||||||||||||||||||||||
Accrued interest..................................................................................... | 21,167 | 26,888 | ||||||||||||||||||||||
Income taxes payable.............................................................................. | 89,273 | 12,613 | ||||||||||||||||||||||
Deferred tax liabilities............................................................................. | 4,786 | 2,227 | ||||||||||||||||||||||
Total current liabilities........................................................................ .. | 430,644 | 525,940 | ||||||||||||||||||||||
Long-term borrowings................................................................................. | 1,299,662 | 1,437,538 | ||||||||||||||||||||||
Deferred tax liabilities.................................................................................. | 324,942 | 324,678 | ||||||||||||||||||||||
Pension and postretirement benefit liabilities...................................................... | 170,016 | 169,841 | ||||||||||||||||||||||
Other liabilities....................................................................................... | 175,570 | 182,864 | ||||||||||||||||||||||
Total liabilities........................................................................ .......... | 2,400,834 | 2,640,861 | ||||||||||||||||||||||
Commitments and contingencies | ||||||||||||||||||||||||
Total common shareholders’ equity.................................................................. | 1,401,329 | 1,246,455 | ||||||||||||||||||||||
Noncontrolling interest.............................................................................. | 4,111 | 39,428 | ||||||||||||||||||||||
Total equity | 1,405,440 | 1,285,883 | ||||||||||||||||||||||
Total liabilities and equity..................................................................... | $ | 3,806,274 | $ | 3,926,744 | ||||||||||||||||||||
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended | ||||||||||||||||||||||||||||||||
March 29, | March 30, | |||||||||||||||||||||||||||||||
2009 | 2008 | |||||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Cash Flows from Operating Activities of Continuing Operations: | ||||||||||||||||||||||||||||||||
Net income .................................................................................. | $ | 225,607 | $ | 29,997 | ||||||||||||||||||||||||||||
Adjustments to reconcile net income to net cash used in operating activities: | ||||||||||||||||||||||||||||||||
Income from discontinued operations.............................................. | (198,957 | ) | (14,789 | ) | ||||||||||||||||||||||||||||
Depreciation expense.................................................................. | 14,509 | 16,266 | ||||||||||||||||||||||||||||||
Amortization expense of intangible assets........................................ | 11,133 | 11,716 | ||||||||||||||||||||||||||||||
Amortization expense of deferred financing costs.............................. | 2,641 | 1,468 | ||||||||||||||||||||||||||||||
Stock-based compensation......................................................... | 2,250 | 1,797 | ||||||||||||||||||||||||||||||
Net loss on sales of businesses and assets........................................... | 2,597 | 18 | ||||||||||||||||||||||||||||||
Other.................................................................................... | 760 | 2,206 | ||||||||||||||||||||||||||||||
Changes in operating assets and liabilities, net of effects of acquisitions: | ||||||||||||||||||||||||||||||||
Accounts receivable.................................................................... | (13,318 | ) | (29,155 | ) | ||||||||||||||||||||||||||||
Inventories............................................................................... | (11,903 | ) | 15,999 | |||||||||||||||||||||||||||||
Prepaid expenses and other current assets......................................... | 1,681 | 669 | ||||||||||||||||||||||||||||||
Accounts payable and accrued expenses............................................. | (36,094 | ) | 1,395 | |||||||||||||||||||||||||||||
Income taxes payable and deferred income taxes................................ | (5,360 | ) | (57,837 | ) | ||||||||||||||||||||||||||||
Net cash used in operating activities from continuing operations......... | (4,454 | ) | (20,250 | ) | ||||||||||||||||||||||||||||
Cash Flows from Financing Activities of Continuing Operations: | ||||||||||||||||||||||||||||||||
Proceeds from long-term borrowings.................................................... | 10,000 | — | ||||||||||||||||||||||||||||||
Reduction in long-term borrowings.................................................... | (249,178 | ) | (13,421 | ) | ||||||||||||||||||||||||||||
Increase in notes payable and current borrowings..................................... | (659 | ) | 10,159 | |||||||||||||||||||||||||||||
Proceeds from stock compensation plans............................................... | 367 | 1,602 | ||||||||||||||||||||||||||||||
Payments to noncontrolling interest shareholders.................................... | (295 | ) | (442 | ) | ||||||||||||||||||||||||||||
Dividends.................................................................................. | (13,511 | ) | (12,622 | ) | ||||||||||||||||||||||||||||
Net cash used in financing activities from continuing operations............ | (253,276 | ) | (14,724 | ) | ||||||||||||||||||||||||||||
Cash Flows from Investing Activities of Continuing Operations: | ||||||||||||||||||||||||||||||||
Expenditures for property, plant and equipment........................................ | (7,020 | ) | (7,468 | ) | ||||||||||||||||||||||||||||
Proceeds from sales of businesses and assets, net of cash sold....................... | 296,883 | — | ||||||||||||||||||||||||||||||
Payments for businesses and intangibles acquired, net of cash acquired........... | (1,108 | ) | (350 | ) | ||||||||||||||||||||||||||||
Investments in affiliates.................................................................... | — | (100 | ) | |||||||||||||||||||||||||||||
Net cash provided by (used in) investing activities from continuing operations..................................................................... | 288,755 | (7,918 | ) | |||||||||||||||||||||||||||||
Cash Flows from Discontinued Operations: | ||||||||||||||||||||||||||||||||
Net cash provided by operating activities................................... | 17,183 | 14,283 | ||||||||||||||||||||||||||||||
Net cash used in financing activities................................................... | (11,075 | ) | (12,250 | ) | ||||||||||||||||||||||||||||
Net cash used in investing activities...................................................... | (1,103 | ) | (291 | ) | ||||||||||||||||||||||||||||
Net cash provided by discontinued operations.................................. | 5,005 | 1,742 | ||||||||||||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents........................ | (254 | ) | (6,085 | ) | ||||||||||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents..................................... | 35,776 | (47,235 | ) | |||||||||||||||||||||||||||||
Cash and cash equivalents at the beginning of the period................................ | 107,275 | 201,342 | ||||||||||||||||||||||||||||||
Cash and cash equivalents at the end of the period........................................ | $ | 143,051 | $ | 154,107 | ||||||||||||||||||||||||||||
TELEFLEX INCORPORATED AND SUBSIDIARIES
SUMMARY OF SEGMENT RESULTS
(Unaudited)
Three Months Ended | ||||||||||||||||||||||||||||||||
March 29, | March 30, | |||||||||||||||||||||||||||||||
2009 | 2008 | |||||||||||||||||||||||||||||||
(Dollars in thousands) | ||||||||||||||||||||||||||||||||
Segment net revenues: | ||||||||||||||||||||||||||||||||
Medical................................................................................................... | $ | 340,542 | $ | 374,057 | ||||||||||||||||||||||||||||
Aerospace................................................................................................ | 43,729 | 66,288 | ||||||||||||||||||||||||||||||
Commercial............................................................................................. | 85,404 | 101,765 | ||||||||||||||||||||||||||||||
Total segment net revenues......................................................................... | 469,675 | 542,110 | ||||||||||||||||||||||||||||||
Segment operating profit (1): | ||||||||||||||||||||||||||||||||
Medical................................................................................................... | 70,193 | 70,912 | ||||||||||||||||||||||||||||||
Aerospace................................................................................................ | 3,037 | 4,928 | ||||||||||||||||||||||||||||||
Commercial............................................................................................. | 4,661 | 2,847 | ||||||||||||||||||||||||||||||
Total segment operating profit..................................................................... | 77,891 | 78,687 | ||||||||||||||||||||||||||||||
Corporate expenses............................................................................................. | 10,767 | 13,008 | ||||||||||||||||||||||||||||||
Loss on sales of businesses and assets.................................................................... | 2,597 | 18 | ||||||||||||||||||||||||||||||
Restructuring and impairment charges..................................................................... | 2,463 | 8,856 | ||||||||||||||||||||||||||||||
Noncontrolling interest (2)................................................................................. | (236 | ) | (187 | ) | ||||||||||||||||||||||||||||
Income from continuing operations before interest, taxes and noncontrolling interest........... | $ | 62,300 | $ | 56,992 | ||||||||||||||||||||||||||||
(1) | Segment operating profit includes a segment’s net revenues reduced by its materials, labor and other product costs along with the segment’s selling, engineering and administrative expenses and noncontrolling interest. Unallocated corporate expenses, loss on sales of assets, restructuring and impairment charges, interest income and expense and taxes on income are excluded from the measure. |
(2) | Noncontrolling interest is included in segment operating profit presented above and must be removed in order to calculate income from continuing operations before interest, taxes and noncontrolling interest, as presented on the Company’s condensed consolidated statements of income for the three months ended March 29, 2009 and March 30, 2008, respectively. |
###
2